Roivant Sciences Ltd. ROIV
Set alert
35.89 USD -1.02 -2.76%
At close · Nov 2
35.89 0.00 0.00%
After hours · Nov 2, 4:00 PM ET
35.81 Day range 37.29
19.30 52-week range 42.50
- YTD
- +65.39%
- 1 year
- +79.54%
- Open
- 36.95
- Prev close
- 36.91
- Mkt cap
- 25.92B
- Vol
- 5.70M
- Avg vol
- 7.63M
- EPS
- -0.53
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 35.81
- High
- 37.29
- Forward P/E
- -25.78
- Beta
- 1.20
- Short ratio
- 5.65
- Inst. own
- 78.60%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 9, 2026
- 50-d avg
- 36.65
- 200-d avg
- 31.50
- 1y target
- 50.00
5Y chart
Events in this range
- Aug 11, 2025Earnings: -0.25175; estimate -0.2497; surprise -0.82%
- Nov 10, 2025Earnings: -0.20193; estimate -0.3198; surprise 36.86%
- Feb 6, 2026Earnings: -0.24; estimate -0.29954; surprise 19.88%
- May 20, 2026Earnings: -0.2792; estimate -0.28931; surprise 3.49%
- Aug 6, 2026Earnings: -0.33; estimate -0.29962; surprise -10.14%
- Sep 8, 2026Rating: HC Wainwright & Co. · Buy → Buy
- Sep 9, 2026Rating: Guggenheim · Buy → Buy
- Sep 9, 2026Rating: TD Cowen · Buy → Buy
- Sep 17, 2026Rating: Stifel · — → Buy
- Oct 12, 2026Downgrade: Wolfe Research · Outperform → Peer Perform
- Oct 28, 2026Rating: Citigroup · Buy → Buy
Signals (96)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Nov 2, 2026 | 23 hours ago |
| SMA: Bullish | Oct 19, 2026 | 2 weeks ago |
| SMA: Bearish | Sep 21, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 21, 2026 | 1 month ago |
| SMA: Bullish | Sep 7, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 7, 2026 | 1 month ago |
| RSI: Overbought | Sep 7, 2026 | 1 month ago |
| SMA: Bearish | Aug 24, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 24, 2026 | 2 months ago |
| RSI: Overbought | Aug 3, 2026 | 3 months ago |
| MACD: Buy Signal | Jun 22, 2026 | 4 months ago |
| RSI: Overbought | Jun 22, 2026 | 4 months ago |
| SMA: Bullish | Jun 8, 2026 | 4 months ago |
| SMA: Bearish | Jun 1, 2026 | 5 months ago |
| SMA: Bullish | May 4, 2026 | 6 months ago |
| SMA: Bearish | Apr 20, 2026 | 6 months ago |
| MACD: Sell Signal | Apr 20, 2026 | 6 months ago |
| MACD: Buy Signal | Apr 13, 2026 | 6 months ago |
| MACD: Sell Signal | Apr 6, 2026 | 7 months ago |
| RSI: Overbought | Mar 30, 2026 | 7 months ago |
| SMA: Bullish | Feb 2, 2026 | 9 months ago |
| MACD: Buy Signal | Feb 2, 2026 | 9 months ago |
| SMA: Bearish | Jan 26, 2026 | 9 months ago |
| MACD: Sell Signal | Jan 26, 2026 | 9 months ago |
| RSI: Overbought | Sep 8, 2025 | 1 year ago |
| SMA: Bullish | Jul 7, 2025 | 1 year ago |
| SMA: Bearish | Jun 30, 2025 | 1 year ago |
| SMA: Bullish | Jun 2, 2025 | 1 year ago |
| SMA: Bearish | May 5, 2025 | 1 year ago |
| SMA: Bullish | Apr 28, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 28, 2025 | 1 year ago |
| SMA: Bullish | Apr 21, 2025 | 1 year ago |
| SMA: Bearish | Jan 6, 2025 | 1 year ago |
| MACD: Sell Signal | Dec 16, 2024 | 1 year ago |
| SMA: Bearish | Dec 9, 2024 | 1 year ago |
| SMA: Bullish | Nov 18, 2024 | 1 year ago |
| SMA: Bullish | Nov 18, 2024 | 1 year ago |
| MACD: Buy Signal | Nov 18, 2024 | 1 year ago |
| SMA: Bearish | Nov 11, 2024 | 1 year ago |
| SMA: Bearish | Nov 11, 2024 | 1 year ago |
| SMA: Bullish | Nov 4, 2024 | 1 year ago |
| MACD: Sell Signal | Nov 4, 2024 | 1 year ago |
| SMA: Bearish | Oct 28, 2024 | 2 years ago |
| SMA: Bullish | Oct 7, 2024 | 2 years ago |
| SMA: Bearish | Sep 23, 2024 | 2 years ago |
| MACD: Buy Signal | Aug 12, 2024 | 2 years ago |
| SMA: Bullish | Aug 5, 2024 | 2 years ago |
| SMA: Bullish | Aug 5, 2024 | 2 years ago |
| SMA: Bearish | Jul 29, 2024 | 2 years ago |
| SMA: Bearish | Jul 22, 2024 | 2 years ago |
| SMA: Bullish | Jul 8, 2024 | 2 years ago |
| SMA: Bullish | Jul 8, 2024 | 2 years ago |
| SMA: Bearish | May 27, 2024 | 2 years ago |
| SMA: Bearish | May 27, 2024 | 2 years ago |
| MACD: Sell Signal | May 20, 2024 | 2 years ago |
| MACD: Buy Signal | Apr 29, 2024 | 2 years ago |
| SMA: Bullish | Apr 22, 2024 | 2 years ago |
| SMA: Bearish | Apr 8, 2024 | 2 years ago |
| SMA: Bullish | Apr 1, 2024 | 2 years ago |
| SMA: Bullish | Mar 25, 2024 | 2 years ago |
| SMA: Bearish | Mar 11, 2024 | 2 years ago |
| MACD: Sell Signal | Mar 11, 2024 | 2 years ago |
| SMA: Bearish | Mar 4, 2024 | 2 years ago |
| MACD: Buy Signal | Feb 12, 2024 | 2 years ago |
| SMA: Bullish | Feb 5, 2024 | 2 years ago |
| SMA: Bullish | Feb 5, 2024 | 2 years ago |
| MACD: Sell Signal | Jan 29, 2024 | 2 years ago |
| SMA: Bearish | Jan 15, 2024 | 2 years ago |
| SMA: Bearish | Jan 15, 2024 | 2 years ago |
| MACD: Buy Signal | Dec 25, 2023 | 2 years ago |
| SMA: Bullish | Dec 11, 2023 | 2 years ago |
| SMA: Bullish | Nov 27, 2023 | 2 years ago |
| SMA: Bearish | Oct 16, 2023 | 3 years ago |
| SMA: Bearish | Oct 2, 2023 | 3 years ago |
| SMA: Bullish | Sep 25, 2023 | 3 years ago |
| SMA: Bearish | Sep 11, 2023 | 3 years ago |
| MACD: Sell Signal | Sep 11, 2023 | 3 years ago |
| SMA: Bullish | Aug 21, 2023 | 3 years ago |
| SMA: Bearish | Aug 14, 2023 | 3 years ago |
| RSI: Overbought | Jul 10, 2023 | 3 years ago |
| MACD: Buy Signal | May 15, 2023 | 3 years ago |
| SMA: Bullish | Apr 17, 2023 | 3 years ago |
| SMA: Bearish | Mar 20, 2023 | 3 years ago |
| SMA: Bullish | Mar 13, 2023 | 3 years ago |
| MACD: Sell Signal | Mar 6, 2023 | 3 years ago |
| SMA: Bearish | Feb 20, 2023 | 3 years ago |
| SMA: Bullish | Feb 13, 2023 | 3 years ago |
| SMA: Bearish | Jan 30, 2023 | 3 years ago |
| RSI: Overbought | Dec 26, 2022 | 3 years ago |
| RSI: Overbought | Dec 12, 2022 | 3 years ago |
| SMA: Bullish | Oct 3, 2022 | 4 years ago |
| SMA: Bullish | Oct 3, 2022 | 4 years ago |
| SMA: Bearish | Aug 15, 2022 | 4 years ago |
| SMA: Bullish | Aug 8, 2022 | 4 years ago |
| SMA: Bullish | Jun 13, 2022 | 4 years ago |
| SMA: Bearish | Jun 6, 2022 | 4 years ago |
Key statistics
- Market cap
- 25.92B
- Enterprise value
- 23.62B
- Trailing P/E
- 0.00
- Forward P/E
- -25.78
- PEG ratio
- 0.00
- Price / sales
- 3441.87
- Price / book
- 6.13
- EPS (TTM)
- -0.53
- Beta
- 1.20
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 7.53M
- Revenue growth
- -33.50%
- Free cash flow
- -1.12B
- Total cash
- 3.84B
- Total debt
- 107.15M
- Return on equity
- -8.52%
- Shares outstanding
- 722.32M
- Short % of float
- 7.56%
- 50-day average
- 36.65
- 200-day average
- 31.50
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 50.00 +39.3% upside
Now 35.89
- Target (low)
- 41.00
- Target (mean)
- 50.00
- Target (high)
- 62.00
Ratings (0m) 13 11 buy · 2 hold · 0 sell
- Strong buy2
- Buy9
- Hold2
- Sell0
- Strong sell0
Next earnings
Nov 9, 2026
Expected Nov 9, 2026. Consensus EPS estimate -0.44866.
Financials — quick view
ROIV Revenue — quarterly 1.44M
ROIV Net income — quarterly -189.84M
ROIV EPS — quarterly -0.26
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 9, 2026 | Sep 30, 2026 | -0.36664 | — | — | — |
| Aug 6, 2026 | Jun 30, 2026 | -0.29962 | -0.33 | -0.03 | -10.14% |
| May 20, 2026 | Mar 31, 2026 | -0.28931 | -0.2792 | +0.01 | +3.49% |
| Feb 6, 2026 | Dec 31, 2025 | -0.29954 | -0.24 | +0.06 | +19.88% |
| Nov 10, 2025 | Sep 30, 2025 | -0.3198 | -0.20193 | +0.12 | +36.86% |
| Aug 11, 2025 | Jun 30, 2025 | -0.2497 | -0.25175 | 0.00 | -0.82% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 28, 2026 | Citigroup | main | Buy | Buy |
| Oct 12, 2026 | Wolfe Research | down | Outperform | Peer Perform |
| Sep 17, 2026 | Stifel | init | — | Buy |
| Sep 9, 2026 | TD Cowen | main | Buy | Buy |
| Sep 9, 2026 | Guggenheim | main | Buy | Buy |
| Sep 8, 2026 | HC Wainwright & Co. | main | Buy | Buy |
About Roivant Sciences Ltd.
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company's lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases. In addition, the company offers delivery platforms comprising a lipid nanoparticle (LNP) platform and a ligand conjugate platform. Roivant Sciences Ltd. was founded in 2014 and is based in London, United Kingdom.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United Kingdom
- Website
- roivant.com
News
- Citigroup Maintains Buy on Roivant Sciences, Raises Price Target to $56
- If You Invested $100 In Roivant Sciences Stock 5 Years Ago, You Would Have This Much Today
- Roivant Sciences Ltd. (ROIV) Discusses Phase 3 Results for Brepocitinib in Non-Infectious Uveitis Transcript
- Why Is Roivant Sciences Stock Surging Wednesday?
- Roivant Sciences' Brepocitinib Delivers Positive Phase III Uveitis Results
- 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- Roivant and Priovant Announce Positive Results in CLARITY-1 and CLARITY-2 Phase 3 Trials for Brepocitinib in Non-Infectious Uveitis (NIU)
- Roivant to Report Financial Results for the Second Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026
- Roivant Sciences Ltd. $ROIV Stock Holdings Lowered by Assenagon Asset Management S.A.
- Here’s How Much You Would Have Made Owning Roivant Sciences Stock In The Last 5 Years
Your note
Sign in to keep a note on ROIV — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| GLINE MATTHEW | Chief Executive Officer | Sale | Apr 15, 2026 | 16,736,100 |
| GOLD DANIEL ALLEN | Director | Sale | Jun 29, 2026 | 0 |
| KUMAR RAKHI | Officer | Sale | Feb 12, 2025 | 163,264 |
| MANCHESTER KEITH S | Director | Stock Award(Grant) | Sep 15, 2026 | 1,753,460 |
| OREN ILAN | Director | Stock Award(Grant) | Oct 22, 2026 | 124,490 |
| PULIK RICHARD | Chief Financial Officer | Stock Award(Grant) | Apr 19, 2026 | 297,511 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 11.22% | 81,020,390 | 2.91B | Jun 29, 2026 |
| Blackrock Inc. | 6.68% | 48,236,091 | 1.73B | Jun 29, 2026 |
| Morgan Stanley | 5.90% | 42,592,905 | 1.53B | Jun 29, 2026 |
| QVT Financial LP | 3.28% | 23,723,074 | 851.42M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 3.06% | 22,123,198 | 794.00M | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 3.00% | 21,641,339 | 776.71M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 3.19% | 23,009,528 | 825.81M | Aug 30, 2026 |
| iShares Trust-iShares Core S&P Mid-Cap ETF | 2.67% | 19,297,013 | 692.57M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.21% | 15,987,737 | 573.80M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 1.60% | 11,546,280 | 414.40M | Jun 29, 2026 |
| Invesco Exchange-Traded Fund Trust-Invesco S&P MidCap Momentum ETF | 0.96% | 6,900,746 | 247.67M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund | 0.92% | 6,658,616 | 238.98M | Jun 29, 2026 |